StockNews.AI
SEPN
StockNews.AI
182 days

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

1. Septerna faces investigation for securities fraud after trial discontinuation. 2. Company halted Phase 1 trial for SEP-786 due to severe bilirubin cases. 3. Stock dropped over 65% after the announcement of trial halt.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The stock's significant drop indicates severe loss of investor confidence, similar to past failures in clinical trials that led to mass sell-offs.

How important is it?

The investigation into possible securities fraud and the halted trials present direct threats to SEPN's valuation and investor trust.

Why Short Term?

Immediate negative sentiment from investors will likely affect stock performance in the near term, as seen in previous cases of trial discontinuations.

Related Companies

SEP-786NASDAQ: SEPN
LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Septerna, Inc. (“Septerna” or “the Company”) (NASDAQ: SEPN) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Septerna investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. On February 18, 2025, Septerna announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R), was being developed for the treatment of hypoparathyroidism. The company stated that this decision was based on the observation of two unexpected severe (Grade 3) cases of elevated unconjugated bilirubin in the MAD portion of the trial, both occurring without corresponding increases in ALT, AST, or GGT liver enzyme levels. Following this announcement, Septerna’s stock plummeted over 65% in pre-market trading on February 18, 2025. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News